Related Experiment Video
Updated: Aug 16, 2026
Quantification of Neurovascular Protection Following Repetitive Hypoxic Preconditioning and Transient Middle Cerebral Artery Occlusion in Mice
Published on: May 4, 2015
Neuroprotective effect of mivazerol, an alpha 2-agonist, after transient forebrain ischemia in rats
T Kimura1, M Sato, T Nishikawa
1Department of Anesthesia and Intensive Care Medicine, Akita University School of Medicine, Akita, Japan. kimtetsu@doc.med.akita-u.ac.jp
Background:
We examined whether mivazerol, an alpha2-agonist, had neuroprotective effects after transient forebrain ischemia in rats.
Methods:
Male Sprague-Dawley rats, anesthetized with halothane, were assigned to one of four groups (n=10 each): control (C, normal saline) and mivazerol 10 microg/kg (M10), 20 microg/kg (M20) and 40 microg/kg (M40) groups. Thirty minutes after drug administration, forebrain ischemia was induced with hemorrhagic hypotension and bilateral carotid artery occlusion for 10 min, and then the brain was reperfused. The neurologic outcome was evaluated 24 h, 48 h and 7 days after ischemia, followed by histologic evaluation.
Results:
The survival rate during 7 days was significantly lower in group M40 than in groups M10 and M20 (P<0.05). The neurologic outcome was significantly better in groups M10 and M20 than in group M40 7 days after ischemia (P<0.05). The number of intact neurons in hippocampal CA1 was significantly greater in group M20 than in the other groups (P<0.05). Neuronal injury in the neocortex was significantly less in group M20 than in groups C and M40 (P<0.05).
Conclusions:
Our results suggest that mivazerol, up to 20 microg/kg, provides neuroprotective effects, whereas 40 microg/kg may exaggerate neuronal injury after transient forebrain ischemia in rats.
Insights
Mivazerol, an alpha2-agonist, shows neuroprotective effects in rats after transient forebrain ischemia at doses up to 20 microg/kg. Higher doses (40 microg/kg) may worsen neuronal injury, impacting survival rates.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Investigating the neuroprotective potential of mivazerol, an alpha2-adrenergic agonist.
- Assessing the effects of mivazerol on brain injury following transient forebrain ischemia.
Purpose of the Study:
- To determine the efficacy of mivazerol in mitigating neuronal damage after ischemic events.
- To evaluate dose-dependent neuroprotective effects of mivazerol.
Main Methods:
- Male Sprague-Dawley rats underwent transient forebrain ischemia induced by hypotension and carotid artery occlusion.
- Rats were administered varying doses of mivazerol (10, 20, 40 microg/kg) or saline.
- Neurologic and histologic outcomes were assessed 24 hours, 48 hours, and 7 days post-ischemia.
Main Results:
- Mivazerol at 10 and 20 microg/kg improved neurologic outcomes and increased neuronal survival in the hippocampus (CA1) and neocortex.
- A higher dose of 40 microg/kg mivazerol resulted in decreased survival rates and exacerbated neuronal injury.
- The 20 microg/kg dose demonstrated the most significant neuroprotective effect.
Conclusions:
- Mivazerol exhibits dose-dependent neuroprotective properties against transient forebrain ischemia in rats.
- Optimal neuroprotection was observed with mivazerol at 20 microg/kg.
- Higher doses of mivazerol (40 microg/kg) may be detrimental, increasing injury and reducing survival.
